Toll Free: 1-888-928-9744

Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 22 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Pipeline Review, H2 2016', provides in depth analysis on Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) targeted pipeline therapeutics. 

The report provides comprehensive information on the Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7)
- The report reviews Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) Overview 5 Therapeutics Development 6 Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Products under Development by Stage of Development 6 Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Products under Development by Therapy Area 7 Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Products under Development by Indication 8 Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Pipeline Products Glance 9 Early Stage Products 9 Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Products under Development by Companies 10 Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Therapeutics Assessment 12 Assessment by Monotherapy/Combination Products 12 Assessment by Mechanism of Action 13 Assessment by Molecule Type 14 Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Companies Involved in Therapeutics Development 15 INOXIA Lifesciences GmbH 15 Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Drug Profiles 16 AW/EPO-002 - Drug Profile 16 Product Description 16 Mechanism Of Action 16 R&D Progress 16 AW/EPO-003 - Drug Profile 17 Product Description 17 Mechanism Of Action 17 R&D Progress 17 AW/EPOPD-01 - Drug Profile 18 Product Description 18 Mechanism Of Action 18 R&D Progress 18 AW/EPOPD-02 - Drug Profile 19 Product Description 19 Mechanism Of Action 19 R&D Progress 19 AW/EPOPD-06 - Drug Profile 20 Product Description 20 Mechanism Of Action 20 R&D Progress 20 Appendix 21 Methodology 21 Coverage 21 Secondary Research 21 Primary Research 21 Expert Panel Validation 21 Contact Us 21 Disclaimer 22
List of Tables
Number of Products under Development for, H2 2016 6 Number of Products under Development by Therapy Area, H2 2016 7 Number of Products under Development by Indication, H2 2016 8 Comparative Analysis by Early Stage Products, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Products under Development by Companies, H2 2016 11 Assessment by Monotherapy/Combination Products, H2 2016 12 Number of Products by Stage and Mechanism of Action, H2 2016 13 Number of Products by Stage and Molecule Type, H2 2016 14 Pipeline by INOXIA Lifesciences GmbH, H2 2016 15



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $3500
Multi User - US $7000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify